IGF1 and cancer: Probably, the effect of this polymorphism on circulating IFGBP-3 levels (estimated in 6–9% of variation) (Jernstrom et al, 2001b; Schernhammer et al, 2003) is not sufficient, by itself, to alter amounts of bioavailable IGF-I sufficiently to lead to a substantial change in cancer risk.